CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project aims to develop core-multishell nanogels for delivering CRISPR-based gene editing tools to treat cystic fibrosis. By enhancing the efficiency of gene delivery, it seeks to address the underlying genetic causes of the disease, potentially leading to effective therapies.
Cystic fibrosis (CF) is the most common genetic lung disease (monogenic autosomal recessive disorder) worldwide and currently there is no cure.
The emergence of powerful gene editing tools like CRISPR-Cas (“clustered regularly interspaced short palindromic repeats/associated protein 9”), now provides the opportunity to correct the disease-causing mutations which can potentially cure CF.
The present research project proposes the development of core-multishell nanogels (NGs) yielding efficient tra…
UNIVERSIDAD DEL PAIS VASCO/ EUSKAL HERRIKO UNIBERTSITATEA
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Spain, VITORIA-GASTEIZ
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Spain, Donostia San Sebastian
Type: Research institute
Activity type: Research Organisations
SME: No
CHARITE - UNIVERSITAETSMEDIZIN BERLIN
Germany, Berlin
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
